1. The American Cancer Society. Liver Cancer 2011.

2. Gu JW, et al. Ethanol stimulates tumor progression and expression of vascular endothelial growth factor in chick embryos. Cancer 2005;103:422-31.

3. Llovet J, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized, placebo-controlled trial (SHARP trial). J Clin Oncol 2007;25;18S (suppl; abstr LBA1).

4. Faivre SJ, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 25 2007;18S (suppl; abstr 3546).

5. Abou-Alfa G, et al. (2007) Preliminary results from a phase 2, randomized, double-blind, study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer 5;259 (suppl; abstr 3500).

6. http://www.pfizer.com/news/press_releases/pfizer_press_releases. Accessed July 12, 2010.

7. Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. Journal of Clinical Oncology [early online publication]. January 12, 2009.

8. Brandi G, et al. (2007) Metronomic capecitabine in advanced patients with hepatocellular carcinoma (HCC): Preliminary results. J Clin Oncol 25;18S (suppl; abstr 15163).

9. Bayer/Onyx. Sorafenib Prescribing Information. Available at: http://www.fda.gov/cder/Offices/OODP/whatsnew/sorafenib.htm. Accessed November 26, 2007.

10. System ENABLE™.